Helixmith Sells US Subsidiary Xenophys for 132 Billion KRW
[Asia Economy Reporter Ji Yeon-jin] Bio-pharmaceutical company Helixmith announced on the 3rd that it will sell all 47.91 million shares of its subsidiary, US-based Xenophys, to Barker Chemical Corporation. The sale price consists of an advance payment of 34.5 billion KRW, and up to 106.4 billion KRW including earn-outs (a portion of profits generated after the M&A) and milestone royalties.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Woman Experiences Eye Protrusion After 20 Years of Contraceptive Injections, Plans Lawsuit Against Major Pharmaceutical Company
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "We will improve management efficiency and financial structure through the share sale," adding, "As a condition of the sale, for the next five years, Xenophys in the US and other regions where Xenophys operates or plans to operate (excluding Korea, China, and Japan) will not engage in the pDNA CDMO business."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
